Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has upgraded Ultragenyx Pharmaceutical (NASDAQ:RARE) from Neutral to Buy and raised the price target from $56 to $67.

June 06, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has upgraded Ultragenyx Pharmaceutical from Neutral to Buy and increased the price target from $56 to $67.
The upgrade from Neutral to Buy and the increased price target from $56 to $67 by Goldman Sachs is likely to positively impact Ultragenyx Pharmaceutical's stock price in the short term. Analyst upgrades typically lead to increased investor confidence and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100